The effect of aspirin on human immunodeficiency virus (hiv) disease progression among hiv- infected individuals initiating antiretroviral therapy.
Phase 2
Suspended
- Conditions
- HIV/AIDS
- Registration Number
- PACTR202003522049711
- Lead Sponsor
- MUHAS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- All
- Target Recruitment
- 454
Inclusion Criteria
Consenting newly recruited male or female HIV-infected patients
ARV drugs naïve initiating on ARV drugs
Aged 18 years and above
Willing to stay in Dar es salaam for at least six consecutive months
Willing to attend HIV clinics at Temeke or Mbagala Rangi Tatu or Mwananyamala hospitals for at least six consecutive months
Exclusion Criteria
Previous intolerance or allergy to ASA or any ASA products
Asthmatics
Current or History of recurrent Peptic Ulcer Disease (PUD)
Predisposition to bleeding
Antithrombotic therapy
Therapy with prohibited drugs (see appendix 5)
Active or history of peptic ulcer disease
Pregnancy
Severe renal disease (eGFR <30 mil/min/1.73 m2)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method